Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600563 | 0.83 | LRRK2 (0.38) | DYRK1A | |
| SCHEMBL2600551 | 0.80 | MAP3K11 (0.43) | METCLK1DYRK1A | |
| SCHEMBL2600540 | 0.80 | JAK3 (0.39) | MAP4K1CLK1DYRK1A | |
| SCHEMBL2115072 | 0.79 | ABL1 (0.50) | MAP4K1CLK1DYRK1A | |
| SCHEMBL2600555 | 0.78 | MAP4K1 (0.40) | MAP4K1RAB9A | |
| SCHEMBL2600566 | 0.76 | CHEK1 (0.34) | — | |
| SCHEMBL5064620 | 0.70 | ABL1 (0.43) | MAP4K1CLK1DYRK1A | |
| SCHEMBL11968645 | 0.70 | SGK1 (0.49) | CLK1DYRK1A | |
| SCHEMBL2600653 | 0.70 | MAP4K1 (0.43) | MAP4K1CLK1DYRK1A | |
| SCHEMBL2600670 | 0.69 | MAP4K1 (0.42) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | PDXK, MAP3K4, PDPK1 | MET 1815/4885MAP4K1 16/4885CLK1 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.